ViiV Healthcare to present data for its next generation of ultra ...
ウェブ2024年2月28日 · GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of 64 abstracts that includes highlights of the company’s next-generation pipeline advancements, alongside data from its diverse …
ViiV Healthcare announces U.S. FDA approval of Dovato ...
ウェブDURHAM, N.C., April 08, 2024 -- ( BUSINESS WIRE )--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the U.S....
ViiV Healthcare Announces Interim Data at CROI Indicating ...
ウェブLONDON, March 06, 2024--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced data from a planned...
ViiV Healthcare presents phase I clinical trial findings of a ...
ウェブLONDON, March 04, 2024 -- ( BUSINESS WIRE )--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings...
ViiV Healthcare and Medicines Patent Pool Announce Major ...
ウェブ30 April 2024. 12:42. Expand. ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, together with the Medicines Patent Pool (MPP), have announced a major milestone in their partnership.
カボテグラビル超長時間作用型製剤の第1相臨床試験の結果に ...
ウェブ2024年3月7日 · 塩野義製薬株式会社（本社：大阪市中央区、代表取締役会長兼社長CEO：手代木 功、以下「塩野義製薬」または「当社」）は、当社がGlaxoSmithKline plc.およびPfizer Inc.とともに資本参加しているViiV Healthcare Ltd.（以下「ViiV社」）が、カボテグラビル超長時間作用型製剤（以下、「CAB-ULA」）について、第1相臨 …
GSKとヴィーブヘルスケア、業界をリードする感染症 ...
ウェブ2023年10月19日 · GSKは、サイエンス、テクノロジー、人財を結集し、力を合わせて病に先手を打つことを存在意義とするバイオ医薬品のグローバルリーダーです。 詳細情報は https://jp.gsk.com をご参照ください。 ヴィーブヘルスケアについて. ヴィーブヘルスケアは、GSKおよびファイザーによって2009年11月に設立された、抗HIV薬に特化 …
ViiV Healthcare reports data from injectable HIV treatment trial
ウェブFebruary 22, 2024. The trial of the long-acting injectable antiretroviral treatment is underway at 31 sites in the US. Credit: LookerStudio / Shutterstock.com. ViiV Healthcare has reported interim analysis data from the LATITUDE Phase III clinical trial of its long-acting injectable antiretroviral treatment (ART) Cabenuva in HIV ...
GSK’s ViiV Healthcare to Share Latest Advances in HIV ...
ウェブ(PRESS RELEASE) LONDON, 19-Oct-2023 — / EuropaWire / — GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced the presentation of key abstracts highlighting the breadth of its approved and investigational medicines at the …
ViiV Healthcare presents phase I clinical trial findings of a ...
ウェブ04 March 2024. Issued: London, UK. For media and investors only. ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months …
- 一部の検索結果が削除されました
コンテンツに移動